Article info
PDFABN Guidelines
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
- Correspondence to Professor Neil Scolding, Bristol Institute of Clinical Neurosciences, Learning and Research Building, Southmead Hospital, Bristol BS10 5NB, UK; n.j.scolding{at}bristol.ac.uk
Citation
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
Publication history
- Accepted May 27, 2015
- First published June 22, 2015.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Disease modifying therapies for relapsing multiple sclerosis
- Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
- Predicting and preventing the future: actively managing multiple sclerosis
- Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis
- Disease-modifying therapies for multiple sclerosis
- Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
- Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
- Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
- Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study
- Multiple sclerosis